Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Feb;6(1):100035.
doi: 10.1016/j.esmoop.2020.100035. Epub 2021 Jan 7.

Dual immune checkpoint inhibition in metastatic renal cell carcinoma: Editorial re.: Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced RCC: extended 4-year follow-up of the phase III CheckMate 214 trial

M Schmidinger  1 , S F Shariat  2 , H Fajkovic  3
Affiliations
Editorial

Dual immune checkpoint inhibition in metastatic renal cell carcinoma: Editorial re.: Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced RCC: extended 4-year follow-up of the phase III CheckMate 214 trial

M Schmidinger et al. ESMO Open. 2021 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Disclosure MS has received honoraria for advisory boards or lectures from Pfizer, BMS, Merck, MSD, Ipsen, Exelixis, EUSA, EISAI, Alkermes; SFS has received honoraria from Astellas, Astra Zeneca, Bayer, BMS, Cepheid, Ferring, Ipsen, Janssen, Lilly, MSD, Olympus, Pfizer, Pierre Fabre, Richard Wolf, Roche, Sanochemia, Sanofi, Takeda, UroGen; had/having consulting or advisory roles in Astellas, Astra Zeneca, Bayer, BMS, Cepheid, Ferring, Ipsen, Janssen, Lilly, MSD, Olympus, Pfizer, Pierre Fabre, Richard Wolf, Roche, Sanochemia, Sanofi, Takeda, UroGen; member of speakers’ bureau in Astellas, Astra Zeneca, Bayer, BMS, Cepheid, Ferring, Ipsen, Janssen, Lilly, MSD, Olympus, Pfizer, Pierre Fabre, Richard Wolf, Roche, Sanochemia, Sanofi, Takeda, UroGen, Movember Foundation; and has filed the following patents: Method to determine prognosis after therapy for prostate cancer (Granted 6 September 2002); Methods to determine prognosis after therapy for bladder cancer; (Granted 19 June 2003); Prognostic methods for patients with prostatic disease (Granted 5 August 2004); Soluble Fas urinary marker for the detection of bladder transitional cell carcinoma (Granted 20 July 2010); HF has nothing to declare.

Comment on

References

    1. Albiges L., Tannir N.M., Burotto M. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open. 2020;5(6) - PMC - PubMed
    1. Heng D.Y., Xie W., Regan M.M. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 2013;14(2):141–148. - PMC - PubMed
    1. Battle D., Bergerot C.D., Msaouel P. Patient preferences and expectations of systemic therapy in renal cell carcinoma. J Clin Oncol. 2020;38(suppl 15):5083.
    1. Shuch B., Amin A., Armstrong A.J. Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity. Eur Urol. 2015;67(1):85–97. - PubMed
    1. Tannir N.M., Signoretti S., Choueiri T.K. Efficacy and safety of nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma. Clin Cancer Res. 2020 doi: 10.1158/1078-0432.CCR-20-2063. - DOI - PMC - PubMed

MeSH terms